Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Syncona

- PMLiVE

Novartis gains rights to Arvinas’ prostate cancer therapy in deal worth over $1bn

The transaction also includes the sale of Arvinas’ preclinical AR-V7 programme

- PMLiVE

Pfizer/Astellas’ Xtandi receives CHMP recommendation to treat recurrent prostate cancer

For nine out of ten patients with nmHSPC with high-risk BCR, their condition will progress into a metastatic disease

- PMLiVE

Revolutionising healthcare: The crucial role of diagnostics in transforming the NHS

Amid the formidable challenges faced by the NHS, Onyx Health delve into the pivotal role of diagnostics in healthcare transformation, showcasing how collaboration, innovation, and patient-centric approaches are revolutionising healthcare...

Onyx Health

- PMLiVE

How does funding flow in NHSE Regions? – Live Webinar

On Friday 23rd February at 2.00pm, we will sit down with guest speaker Richard Smale (Interim Director of System Co-ordination, NHS England [NHSE] – South West) for an all-encompassing discussion...

Mtech Access

- PMLiVE

MHRA sets out regulatory roadmap to support safe access to medical technology

The new regulations will ensure patients have access to the medical devices they need without delay

- PMLiVE

ICR study predicts response to radium-233 treatment in prostate cancer bone metastases

The findings could help determine which patients would benefit from the treatment

- PMLiVE

AstraZeneca/Merck’s Lynparza recommended by NICE for advanced prostate cancer

The combination therapy has been recommended for patients regardless of biomarker status

Mtech Access certified as a NICE META tool facilitating organisation

Mtech Access are now a certified NICE META Tool facilitating organisation, with three experts having passed the NICE assessment

Mtech Access

- PMLiVE

Pfizer and Astellas’ Xtandi approved by FDA for earlier prostate cancer indication

Xtandi is the first androgen receptor signalling inhibitor approved for this patient population

- PMLiVE

New genetic variants linked to prostate cancer in men with African ancestry

A dataset was compiled for the research containing DNA from over 944,000 men

- PMLiVE

Scientists discover way to reverse drug resistance in prostate cancer

Targeting ‘hijacked’ white blood cells could reverse drug resistance and slow tumour progression

- PMLiVE

International study reveals 11 new genes linked to aggressive prostate cancer

Findings from the study could improve treatment options for patients with prostate cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links